Patients were considered to have "severe heart failure" if their condition before use of nifekalant was: (i) New York Heart Association classification III or IV; (ii) Killip's classification II, III, or IV; (iii) Forrester's subset II, III, or IV; (iv) left ventricular ejection fraction (LVEF) <40%, or if they were confirmed to: (v) have placement of a percutaneous cardiopulmonary support system (PCPS); (vi) have placement of a left ventricular assist device (LVAD); (vii) be in cardiogenic shock; or (viii) be in cardiopulmonary arrest.
Investigation of Occurrence of Arrhythmia After Use of Nifekalant
Of those who were given a single intravenous dose of nifekalant, patients for whom administration was initiated during the attack of arrhythmia were investigated to determine whether the attack was terminated and, if terminated, the time required from beginning of administration to termination of attack.
For those who had direct-current (DC) shock-resistant VT or VF, effects of additional DC shock after intravenous administration of nifekalant were investigated.
For those given maintenance infusion of nifekalant, we investigated if there were any recurrences.
In addition, for those for whom termination of VT was not achieved, we investigated the rate of tachycardia immediately before and after the intravenous administration of nifekalant.
Furthermore, QT intervals, corrected QT (QTc), heart rate, blood pressure, as well as hemodynamics parameters including fractional shortening (%FS), LVEF, cardiac output, and pulmonary capillary wedge pressure (PCWP) were checked before and after administration.
Efficacy Evaluation
Termination of Arrhythmias Efficacy of single administration of nifekalant in terminating VT or VF was assessed based on the following criteria: "Effective": (i) Single administration of nifekalant successfully terminated VT or VF.
(ii) DC shock before intravenous administration of nifekalant was not effective in terminating VT or VF, but additional DC shock after use of nifekalant successfully terminated them (this is regarded as "enhancement of defibrillating effect"). "Not effective": (i) Single administration of nifekalant failed to terminate VT or VF.
(ii) DC shock before intravenous administration of nifekalant was not effective in terminating VT or VF, and additional DC shock after use of nifekalant also failed to terminate them. "Aggravated": The time from refractory to treatment was increased (for example, termination of the arrhythmia was more difficult compared with before use of intravenous nifekalant). Cases were judged "not evaluated" when another antiarrhythmic drug was used at the same time with (or immediately after) administration of nifekalant, or the patient was started on treatment with PCPS, LVAD, or other assisted circulation system.
Prevention of Recurrence of Arrhythmia Efficacy of maintenance infusion of nifekalant in preventing the recurrence VT or VF was assessed based on the following criteria: "Effective": (i) During maintenance infusion of the drug, recurrence of sustained VT or VF was completely suppressed.
(ii) During maintenance infusion of the drug, recurrence was noted, but not after increase in dose of nifekalant.
(iii) During maintenance infusion of the drug, recurrence of sustained VT could not be suppressed, but VF, which had occurred at least twice before intravenous administration of nifekalant, was completely suppressed. "Not effective": (i) Cases not meeting any of the above criteria "effective", but without aggravation. (ii) Recurrence of sustained VT or VF was noted during maintenance infusion of the drug. "Aggravated": Frequency of the arrhythmia increased under treatment. Cases were judged "not evaluated" when the maintenance infusion was started during VT or VF; another antiarrhythmic drug was used at the same time with infusion of nifekalant; or the patient was started on treatment with PCPS, LVAD, or other assisted circulation system.
Outcome After Completion of Nifekalant Administration
Patient outcome (survival status, ie, alive or dead) was investigated 30 days after completion of nifekalant administration.
Safety
Of the symptoms and abnormal changes in laboratory tests noted during or after administration of nifekalant, those for which a relationship to nifekalant could not be ruled out were considered as adverse drug reactions.
Statistics
Values are expressed as mean ± SD. For efficacy analysis, 95% confidence intervals (CIs) were calculated. Participation of patient characteristics on the efficacy and safety were analyzed using Fisher's exact probability test. Paired t-test was used for comparison before and after nifekalant administration. P-values less than 0.05 were considered significant.
Results

Patients' Eligibility
As shown in Fig 1, a total of 191 patients were included in the safety analysis. Seventeen patients, who were given nifekalant for off-label use such as treatment of atrial fibrillation or for an electrophysiological study, were excluded from the efficacy analysis. All of the 93 eligible patients were evaluated for arrhythmia termination. However, 31 out of 130 eligible patients were judged "not evaluated" for prevention of recurrence. Table 1 shows the patient characteristics. A total of 182 patients had underlying heart diseases including acute myocardial infarction. Most patients had "severe heart failure". Class Ib anti-arrhythmic drugs, amiodarone, and catecholamines were frequently used concomitantly.
Clinical Characteristics
Efficacy
Termination of Arrhythmias Termination of sustained (Fig 4) .
Patient Characteristics and Effectiveness There were no differences in the patient characteristics that affected the efficacy of nifekalant in terms of either terminating VT or VF (Table 2 ) or preventing recurrence of arrhythmias (Table 3) .
Prognosis
A total of 93 out of 147 patients (63.3%) were alive at 30 days after completion of administration of nifekalant. Major causes of death were heart failure, recurrence of VT/VF, and multiple organ failure. There was no significant difference in survival rate between the "effective" and "not effective" groups for either type of arrhythmias.
For 38 patients with DC shock-resistant VT/VF, survival rate tended to be higher in the "effective" group (45.8%) than in the "not effective" group (21.4%), although not to a significant extent (Fig 5) .
Safety
Excessive prolongation of QT interval (QTc >0.5) was noted in 11 patients (11 episodes). Pro-arrhythmia was Mild changes in liver function tests and results of urinalysis were observed. The incidence of adverse drug reactions is listed in Table 4 .
Heart Rate During VT
In patients with VT that persisted even after single intravenous administration of nifekalant, the tachycardia rate was significantly decreased after administration (before treatment: 174.6±44.1 beats/min, after treatment: 160.6± 45.3 beats/min; n=20, p=0.0019).
Blood Pressure
Nifekalant significantly decreased both systolic blood pressure (before treatment: 119.8±23.1 mmHg, during treat- 
QTc
QTc during sinus rhythm was significantly prolonged after administration of nifekalant (before treatment: 0.463± 0.056, after treatment: 0.504±0.072; n=43, p=0.0018).
Hemodynamic Parameters
Hemodynamic parameters tended to improve after maintenance infusion of nifekalant (%FS: before treatment: 17.1±5.5%, during treatment: 19.3±8.4%; n=10, p=0.2388, ejection fraction: before treatment: 31.6±9.8%, during treatment: 37.7±14.9%; n=10, p=0.0793, PCWP: before treatment: 16.8±7.6 mmHg, during treatment: 15.0±5.9 mmHg; n=20, p=0.2222), although not to a significant extent.
Discussion
Anti-Arrhythmic Efficacy
Lidocaine has been widely used as a conventional agent for treatment of life-threatening ventricular arrhythmias. However, previous reports indicated that the efficacy of lidocaine in terminating VT was low, at only 8-19%. [8] [9] [10] In the present study, intravenous administration of nifekalant successfully terminated VT/VF at around 50% and prevented the recurrence of refractory VT/VF at about 60%. Most of the patients for whom nifekalant was effective in the current study were refractory to lidocaine or other antiarrhythmic drugs, however the present study was not randomized and it was done in a limited situation as described above. Several case reports recently available report on the superior efficacy of nifekalant even in patients with postoperative refractory VT/VF, 11 or in a patient with severe renal failure. 12 Only intravenous amiodarone has revealed a high degree of efficacy nearly comparable with this drug, but it is not yet available on the Japanese market.
Defibrillation-Enhancing Effect
Of patients not responding to the first DC shock, additional DC shock yielded successful cardioversion to sinus rhythm in about half of the cases after nifekalant administration. It is possible that nifekalant enhanced the defibrillating effect of DC current by lowering the defibrillation threshold of myocardium. 10 Most class III anti-arrhythmic agents might have this kind of effect. Some experimental studies have proven the contribution of potassium channelblocking effects of these agents in lowering the defibrillation threshold.
However, class I anti-arrhythmic agents usually increase the defibrillation threshold by blocking sodium channels, but thereby increase the difficulty of electrical defibrillation after drug administration.
Lowering of Tachycardia Rate
In patients who failed to terminate VT, even after a single administration of nifekalant, their heart rate during VT significantly decreased. It is conceivable that the mechanism of termination of VT by nifekalant involves prolongation of the tachycardia cycle length associated with a prolonged effective refractory period.
In relation to this, it can be expected that a decrease in VT rate will reduce the likelihood of hemodynamic deterioration in VT patients. This property of nifekalant is also considered therapeutically beneficial.
Long-Term Outcome
Of patients with DC shock-resistant VT/VF, survival rate was two-fold or higher in those achieving arrhythmia termination after nifekalant. It can be thought that the defibrillation-enhancing effect of nifekalant resulted in the improvement of the prognosis of life-threatening VT/VF.
Adverse Effects
Pro-arrhythmic effect of nifekalant was considered to be the most important adverse reaction. Pro-arrhythmias including Tdp and VT associated with excessive QT prolongation were observed predominantly during maintenance infusion of nifekalant. It is thus considered important to monitor QT interval frequently during nifekalant infusion with adequate dose adjustment.
Nifekalant had no adverse effect on hemodynamics, and even in part improved it. It is suggested that nifekalant increased intracellular calcium concentration associated with the prolongation of action potential duration resulting in the increase of myocardial contraction. 13 
